Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.4
USD
|
+3.34%
|
|
-10.05%
|
-61.32%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
821.4
|
1,886
|
1,172
|
1,519
|
771.9
|
354.3
|
-
|
-
|
Enterprise Value (EV)
1 |
531.3
|
1,630
|
1,172
|
1,519
|
1,064
|
663.2
|
583.9
|
567.1
|
P/E ratio
|
-4.42
x
|
-5.83
x
|
-3.91
x
|
-3.77
x
|
-2.3
x
|
-1.64
x
|
-3.22
x
|
-53.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,989
x
|
123
x
|
15.1
x
|
11.5
x
|
3.3
x
|
1.26
x
|
0.92
x
|
0.7
x
|
EV / Revenue
|
1,286
x
|
106
x
|
15.1
x
|
11.5
x
|
4.54
x
|
2.36
x
|
1.51
x
|
1.12
x
|
EV / EBITDA
|
-3.29
x
|
-6.2
x
|
-4.6
x
|
-4.93
x
|
-6.65
x
|
-6.78
x
|
-83.8
x
|
7.48
x
|
EV / FCF
|
-4.81
x
|
-8.93
x
|
-5.05
x
|
-7.72
x
|
-4.76
x
|
-5.19
x
|
-14.2
x
|
12.2
x
|
FCF Yield
|
-20.8%
|
-11.2%
|
-19.8%
|
-13%
|
-21%
|
-19.3%
|
-7.06%
|
8.16%
|
Price to Book
|
-
|
-
|
-
|
-
|
-5.1
x
|
-1.31
x
|
-1.78
x
|
-2.07
x
|
Nbr of stocks (in thousands)
|
50,608
|
66,549
|
71,795
|
82,274
|
87,813
|
104,216
|
-
|
-
|
Reference price
2 |
16.23
|
28.34
|
16.32
|
18.46
|
8.790
|
3.400
|
3.400
|
3.400
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.413
|
15.32
|
77.8
|
132.6
|
234
|
281.5
|
386.1
|
504.9
|
EBITDA
1 |
-161.6
|
-262.9
|
-254.8
|
-308.2
|
-160.1
|
-97.85
|
-6.968
|
75.82
|
EBIT
1 |
-164.5
|
-273.2
|
-274.7
|
-342
|
-316.8
|
-177.9
|
-80.89
|
16.9
|
Operating Margin
|
-39,820.58%
|
-1,782.46%
|
-353.06%
|
-257.95%
|
-135.35%
|
-63.21%
|
-20.95%
|
3.35%
|
Earnings before Tax (EBT)
1 |
-159.4
|
-284.7
|
-281.3
|
-355.7
|
-323.7
|
-184.8
|
-93.61
|
14.11
|
Net income
1 |
-159.4
|
-282.1
|
-281.3
|
-356.4
|
-324
|
-185.2
|
-89.88
|
11.33
|
Net margin
|
-38,602.66%
|
-1,840.71%
|
-361.59%
|
-268.87%
|
-138.43%
|
-65.8%
|
-23.28%
|
2.24%
|
EPS
2 |
-3.670
|
-4.860
|
-4.170
|
-4.900
|
-3.830
|
-2.070
|
-1.057
|
-0.0640
|
Free Cash Flow
1 |
-110.5
|
-182.6
|
-231.9
|
-196.8
|
-223.5
|
-127.8
|
-41.25
|
46.3
|
FCF margin
|
-26,766.59%
|
-1,191.52%
|
-298.1%
|
-148.42%
|
-95.48%
|
-45.4%
|
-10.68%
|
9.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
61.06%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
408.6%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
19.74
|
25.95
|
25.26
|
28.37
|
29.02
|
49.92
|
49.33
|
58.13
|
56.78
|
69.8
|
56.66
|
68.19
|
69.67
|
85.28
|
79.4
|
EBITDA
|
-67.57
|
-56.18
|
-56.84
|
-52.39
|
-72.04
|
-126.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-72.72
|
-61.6
|
-62.22
|
-57.84
|
-77.48
|
-144.4
|
-58.03
|
-65.5
|
-139.3
|
-53.95
|
-68.78
|
-42.17
|
-40.4
|
-27.43
|
-
|
Operating Margin
|
-368.31%
|
-237.39%
|
-246.31%
|
-203.9%
|
-267.05%
|
-289.28%
|
-117.64%
|
-112.67%
|
-245.34%
|
-77.3%
|
-121.39%
|
-61.85%
|
-58%
|
-32.16%
|
-
|
Earnings before Tax (EBT)
1 |
-74.38
|
-63.1
|
-64.34
|
-61.44
|
-83.99
|
-146
|
-59.79
|
-67.32
|
-140.9
|
-55.7
|
-70.29
|
-44.14
|
-42.45
|
-29.59
|
-
|
Net income
1 |
-74.38
|
-63.1
|
-64.34
|
-61.44
|
-84.69
|
-146
|
-59.79
|
-67.32
|
-141.2
|
-55.7
|
-70.29
|
-44.14
|
-42.45
|
-29.59
|
-
|
Net margin
|
-376.68%
|
-243.15%
|
-254.71%
|
-216.56%
|
-291.89%
|
-292.37%
|
-121.21%
|
-115.8%
|
-248.65%
|
-79.8%
|
-124.07%
|
-64.74%
|
-60.94%
|
-34.7%
|
-
|
EPS
2 |
-1.100
|
-0.9300
|
-0.9400
|
-0.8800
|
-1.170
|
-1.900
|
-0.7400
|
-0.8000
|
-1.630
|
-0.6200
|
-0.7160
|
-0.5060
|
-0.4800
|
-0.3740
|
-0.4900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/28/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/8/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
292
|
309
|
230
|
213
|
Net Cash position
1 |
290
|
256
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.823
x
|
-3.156
x
|
-32.95
x
|
2.806
x
|
Free Cash Flow
1 |
-111
|
-183
|
-232
|
-197
|
-223
|
-128
|
-41.3
|
46.3
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-879%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
-1.720
|
-2.600
|
-1.920
|
-1.640
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.660
|
-2.560
|
-
|
-
|
-
|
Capex
1 |
3.24
|
4.1
|
10.4
|
3.21
|
6.89
|
7.5
|
8.75
|
9.75
|
Capex / Sales
|
784.02%
|
26.74%
|
13.34%
|
2.42%
|
2.94%
|
2.66%
|
2.27%
|
1.93%
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Average target price
16.33
USD Spread / Average Target +380.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -61.32% | 354M | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|